



NZX/ASX Announcement

3 June 2026

Director Appointment/Retirement

TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or the Company), a global leader in AI-enabled cervical cancer screening, is pleased to announce the appointment of Mr. Reece O’Connell as an independent Non-Executive Director of the Company with effect from today’s date.

Mr. O’Connell is an experienced board Chairman, Non-Executive Director and fund manager with deep experience across the biotechnology investment and commercialisation lifecycle, spanning asset selection, capital formation, governance, and international market development.

Mr. O’Connell has an MBA (University of Canberra), Bachelor of Business, Finance (Murdoch University) and a Graduate Diploma of Financial Planning (Kaplan). Mr. O’Connell is currently Chairman of Nexsen Limited (ASX:NXN), Non-Executive Director of RooLife Group (ASX:RLG) and Funds Manager of Summit Funds Management, Biotechnology Fund.

As foreshadowed in the NZX/ASX announcement dated 1 April 2026, Mr. Chris Horn, who has served as a Director of the Company for 13 years retires as at today’s date.

Non-Executive Chairman Tony Ho commented, “*Reece has significant relevant experience in Biotech and we welcome him to the TruScreen Board at a time of significant opportunity. The Board will continue to ensure that it has the appropriate skill mix to guide the Company’s next phase of growth.*”

We thank Chris for a significant contribution over many years, and wish him well in retirement.”

This announcement has been approved by the Board.

Tony Ho
Non-Executive Chairman

Ends

For more information, visit www.truscreen.com or contact:

Tony Ho
Non-Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Omar Taheri
Media & Investor Relations
omar@sparkplus.org



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures

an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.



About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.

DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.